Prompt Arrival of Antivirals against Hepatitis C for HIV Patients
Pablo Barreiro 1, Eugenia Vispo 2
1 Department of Infectious Diseases, Hospital Carlos III-La Paz University Hospital. Madrid, Spain; 2 NULL
*Correspondence: Eugenia Vispo, Email not available
Abstract
The recent release of the phase III results of the new protease inhibitors (telaprevir, boceprevir) developed against HCV has been a major event in the field. The figures below depict the rate of sustained virologic response (SVR) using these drugs in combination with peginterferon plus ribavirin. On appropriate treatment schedules, 75% of genotype 1 subjects treated with telaprevir and 68% of those treated with boceprevir will be cured. Although the rates in patients with prior failure to interferon-based therapies are lower, they are still good, particularly in the subset of prior relapsers, going down to of 20-25% in prior nonresponders.
